Brazil's SaMD Surprise: Hacking ANVISA's New Rules | A Pure Global LATAM MedTech Insight

This episode of LATAM MedTech Insights dives into the critical new regulatory guidance from Brazil's ANVISA for Software as a Medical Device (SaMD). As Brazil doubles down on localized requirements, we explore why simply having FDA or CE approval is no longer enough to guarantee market access. We uncover the hidden complexities of ANVISA's risk classification and the growing importance of local data and cybersecurity compliance. We examine a case study of a digital health company whose market launch was delayed by nine months due to unexpected data privacy requirements. This costly setback highlights a critical pain point: underestimating Brazil's unique regulatory interpretation can derail your entire market entry strategy, even with a globally successful product. Key Questions Answered: - Is ANVISA's evolving SaMD framework a hidden barrier or a clear pathway for prepared companies? - How can your SaMD's risk classification unexpectedly change when entering Brazil? - What are the three most common LGPD (Brazil's Data Protection Law) mistakes foreign MedTech firms make? - Why is your choice of a local Brazil Registration Holder (BRH) more critical than ever for software devices? - What post-market surveillance strategies for SaMD will satisfy ANVISA's new focus? - How can you leverage your existing clinical data for the Brazilian market without starting from scratch? Navigating global markets requires more than just a great product; it demands expert regulatory strategy. Pure Global offers end-to-end solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline market access in over 30 countries, including Brazil. Whether you're a startup or a multinational, we are your local representative, ensuring a clear path to registration and post-market compliance. Don't let regulatory hurdles block your growth. Contact us at [email protected] or visit https://pureglobal.com to learn more.